Literature DB >> 29335525

Urothelial cancer: Optimizing and integrating cisplatin-based chemotherapy across the disease spectrum.

Jay D Raman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29335525     DOI： 10.1038/nrurol.2017.213

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

Authors:  Rafael Morales-Barrera; Joaquim Bellmunt; Cristina Suárez; Claudia Valverde; Marta Guix; Cesar Serrano; Manuel Gallén; Joan Carles
Journal:  Eur J Cancer       Date:  2012-05-16       Impact factor: 9.162

Review 2.  Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.

Authors:  Atiqullah Aziz; Jakub Dobruch; Kees Hendricksen; Luis A Kluth; Andrea Necchi; Aidan Noon; Michael Rink; Florian Roghmann; Roland Seiler; Paolo Gontero; Wassim Kassouf; Shahrokh F Shariat; Evanguelos Xylinas
Journal:  World J Urol       Date:  2017-01-10       Impact factor: 4.226

3.  Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.

Authors:  Sima Porten; Arlene O Siefker-Radtke; Lianchun Xiao; Vitaly Margulis; Ashish M Kamat; Christopher G Wood; Eric Jonasch; Colin P N Dinney; Surena F Matin
Journal:  Cancer       Date:  2014-03-13       Impact factor: 6.860

4.  Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

Authors:  Guru Sonpavde; Deidre Watson; Marcia Tourtellott; C Lance Cowey; Beth Hellerstedt; Thomas E Hutson; Feng Zhan; Nicholas J Vogelzang
Journal:  Clin Genitourin Cancer       Date:  2012-03       Impact factor: 2.872

5.  Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy.

Authors:  Brian R Lane; Armine K Smith; Benjamin T Larson; Michael C Gong; Steven C Campbell; Derek Raghavan; Robert Dreicer; Donna E Hansel; Andrew J Stephenson
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

6.  Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Matthew Kaag; Landon Trost; R Houston Thompson; Ricardo Favaretto; Vanessa Elliott; Shahrokh F Shariat; Alexandra Maschino; Emily Vertosick; Jay D Raman; Guido Dalbagni
Journal:  BJU Int       Date:  2014-10-03       Impact factor: 5.588

Review 7.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Authors:  Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora N Sternberg; Dean F Bajorin; Joaquim Bellmunt
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 8.  Chemotherapy of urothelial tract tumors.

Authors:  A Yagoda
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

9.  High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy.

Authors:  Jay D Raman; Yu-Kuan Lin; Matthew Kaag; Timothy Atkinson; Paul Crispen; Mark Wille; Norm Smith; Mark Hockenberry; Thomas Guzzo; Benoit Peyronnet; Karim Bensalah; Jay Simhan; Alexander Kutikov; Eugene Cha; Michael Herman; Douglas Scherr; Shahrokh F Shariat; Stephen A Boorjian
Journal:  Urol Oncol       Date:  2013-10-17       Impact factor: 3.498

10.  Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Authors:  A Bamias; K Tzannis; L C Harshman; S J Crabb; Y-N Wong; S Kumar Pal; U De Giorgi; S Ladoire; N Agarwal; E Y Yu; G Niegisch; A Necchi; C N Sternberg; S Srinivas; A Alva; U Vaishampayan; L Cerbone; M Liontos; J Rosenberg; T Powles; J Bellmunt; M D Galsky
Journal:  Ann Oncol       Date:  2018-02-01       Impact factor: 51.769
  10 in total
  2 in total

1.  Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer.

Authors:  Xuan Yi; Hailin Zhou; Yu Chao; Saisai Xiong; Jing Zhong; Zhifang Chai; Kai Yang; Zhuang Liu
Journal:  Sci Adv       Date:  2020-08-14       Impact factor: 14.136

2.  Bacteria-Elicited Specific Thrombosis Utilizing Acid-Induced Cytolysin A Expression to Enable Potent Tumor Therapy.

Authors:  Wenjun Qin; Wenxuan Xu; Longyu Wang; Debao Ren; Yibin Cheng; Wen Song; Tao Jiang; Lixin Ma; Cheng Zhang
Journal:  Adv Sci (Weinh)       Date:  2022-04-11       Impact factor: 17.521
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.